NCT04348838 Prospective Cohort of Patients With Hepatocellular Carcinoma in France
| NCT ID | NCT04348838 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Cancer of Liver |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2019-09-26 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2019-09-26 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France, 8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this cancer. The 5-year survival rate is 10%, one of the lowest survival rates of all cancer types. HCC raises a number of major challenges: HCC is discovered at a curable stage in only 25% of cases, reflecting the marked delay in the diagnosis of early stages. The state of knowledge about HCC is well behind that of other cancers (no biomarker, complex carcinogenesis, influence of the aetiology, poorly valorised data, etc.). Rapid technological progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities. The CHIEF project constitutes a common basis knowledge for research project using prospectively collected data in patients with HCC, regardless of the cause and stage of the cancer. This project is a Multicentre longitudinal observational study of patients with HCC with prospective data collection on inclusion and patient follow-up. Constitution of a biological resources collection. 5,000 patients will be included over 2 years with a follow-up of patients of 5 years.
Eligibility Criteria
Inclusion Criteria: * New cases of HCC * suspected case of HCC regardless of the cause, stage, treatment * Known HCC: drug treatment for recurrence or progression Exclusion Criteria: * Associated serious condition threatening life in the short term (with the exception of liver disease itself) * So-called vulnerable populations: minors, persons under guardianship or temporary guardianship, or person deprived of their liberty by an administrative or judicial decision
Contact & Investigator
Jean-Claude BARBARE, Pr
PRINCIPAL INVESTIGATOR
CHU Amiens
Frequently Asked Questions
Who can join the NCT04348838 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer of Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04348838 currently recruiting?
Yes, NCT04348838 is actively recruiting participants. Contact the research team at ganry.olivier@chu-amiens.fr for enrollment information.
Where is the NCT04348838 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT04348838 clinical trial?
NCT04348838 is sponsored by Centre Hospitalier Universitaire, Amiens. The principal investigator is Jean-Claude BARBARE, Pr at CHU Amiens. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.